Zomedica Corp. Announces Results of 2026 Annual Shareholder Meeting

Zomedica Corp. (OTCQB: ZOMDF), a company specializing in pharmaceutical preparations for the veterinary market, has released the official results of its Annual Meeting of Shareholders held on June 10, 2026, in Ann Arbor, Michigan. The company filed a Form 8-K with the SEC to disclose the details and outcomes of the meeting, which included several key proposals that could hold important implications for investors and the company’s future strategic direction.

Key Points from the Shareholder Meeting

• All Eight Director Nominees Elected: Zomedica shareholders voted to elect eight directors to the board, each to serve for a one-year term set to expire at the 2027 annual meeting.
• Auditor Ratified: Grant Thornton LLP was re-appointed as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Executive Compensation Proposal Rejected: Shareholders did not approve, on an advisory basis, the compensation of the company’s named executive officers.
• By-Laws Amended Regarding Quorum for Adjourned Meetings: Shareholders voted in favor of an amendment to the company’s By-Laws to address quorum requirements for adjourned meetings of shareholders.

Detailed Breakdown of Proposals and Results

1. Election of Directors
   
   • All eight nominees were elected to the board for one-year terms. The votes for each director were as follows:
     • For: 148,997,578
     • Withheld: 80,184,510
     • Broker Non-Votes: 200,401,611

   Significance: The re-election of the full slate of directors provides continuity in governance, which may be viewed favorably by investors seeking stability.

2. Ratification of Grant Thornton LLP as Independent Auditors
   
   • For: 403,285,558
     Withheld: 26,298,141

   Significance: The ratification of a recognized audit firm helps reinforce transparency and credibility in Zomedica’s financial reporting.

3. Advisory Vote on Executive Compensation
   
   • For: 99,891,977
     Against: 129,290,109
     Broker Non-Votes: 200,401,613

   Shareholders rejected the executive compensation package.

   Significance: This is a potentially price-sensitive development and may impact share value. A failed “say-on-pay” vote signals shareholder dissatisfaction with the company’s executive pay practices. This may prompt the board and management to reevaluate compensation policies and could foreshadow leadership changes or additional governance reforms. Such shareholder activism may impact market perceptions and could result in volatility in Zomedica’s share price.

4. Amendment to By-Laws on Quorum Requirements
   
   • For: 123,410,315
     Against: 105,771,772
     Broker Non-Votes: 200,401,613

   Significance: The amendment addresses quorum requirements for adjourned meetings, potentially making it easier to conduct business if initial meetings fail to reach a quorum. This procedural change can streamline governance but is less likely to have a direct impact on share price.

Additional Shareholder Information

• Trading Symbol: ZOMDF (OTCQB)
• Company Address: 1101 Technology Drive, Suite 100, Ann Arbor, MI 48108
• Telephone: (734) 369-2555

Potential Price-Sensitive Takeaways for Investors

• The failure of the executive compensation proposal is the most significant item for investors. It highlights potential shareholder unrest and could lead to changes in management practices, compensation structures, or even board composition if not adequately addressed. Investors should monitor the company’s response to this vote in future disclosures or communications.
• The election of all directors and ratification of auditors suggest operational stability, while the By-Law amendment displays a focus on improving governance efficiency.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. The information herein is based on official filings and may be subject to change or updates by Zomedica Corp.

View Zomedica Corp. Historical chart here